Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Marie L. De Bruin"'
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Mandatory pediatric legislation has been implemented in the European Union (EU) and the United States (US) to increase research and the availability of drugs for the pediatric population. Differences in the legislative framework can cause different p
Externí odkaz:
https://doaj.org/article/76ced31c8dcb40fbbbeb8b58b790bd4c
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: The target product profile (TPP) outlines the desired profile of a target product aimed at a particular disease and is used by companies to plan clinical development. Considering the increasing importance of health technology assessment (
Externí odkaz:
https://doaj.org/article/d25677fa677b4d608b735843d9929e4a
Autor:
Heleen K. Bronsveld, Marie L. De Bruin, Jelle Wesseling, Joyce Sanders, Ingrid Hofland, Vibeke Jensen, Marloes T. Bazelier, Bas ter Braak, Anthonius de Boer, Peter Vestergaard, Marjanka K. Schmidt
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background The insulin receptor (INSR) and the insulin growth factor 1 receptor (IGF1R) play important roles in the etiology of both diabetes mellitus and breast cancer. We aimed to evaluate the expression of hormone and insulin-related prot
Externí odkaz:
https://doaj.org/article/694fef545aba4c049b75eb8ee1c082eb
Autor:
Charlotte Rietbergen, Gudrun Stefansdottir, Hubert G. Leufkens, Mirjam J. Knol, Marie L. De Bruin, Irene Klugkist
Publikováno v:
Frontiers in Medicine, Vol 4 (2018)
The current system of harm assessment of medicines has been criticized for relying on intuitive expert judgment. There is a call for more quantitative approaches and transparency in decision-making. Illustrated with the case of cardiovascular safety
Externí odkaz:
https://doaj.org/article/508d74a5a6fc4adebf7fe2c61f2dbca1
Publikováno v:
International Journal of Technology Assessment in Health Care. 39
Background Multi-stakeholder interactions have evolved at product and policy levels. There is a need to assess the current and future landscape of interactions between companies, and regulatory and HTA agencies to address challenges and identify area
Autor:
Ameet Sarpatwari, Marie L. De Bruin, Joel Lexchin, Ruth Lopert, Barbara Mintzes, Alice Bhasale, Priya Bahri
Publikováno v:
Clinical Pharmacology and Therapeutics, 109(6), 1424. Nature Publishing Group
In the wake of the withdrawal of the nonsteroidal anti-inflammatory drug rofecoxib, regulators worldwide reconsidered their approach to postmarket safety. Many have since adopted a “life cycle” approach to regulation of medicines, facilitating fa
Autor:
Bernard Appiah, Mohsen Mazidi, Danny Liew, Maarit Jaana Korhonen, Berhe W. Sahle, Oyepeju Ogundipe, Andrew McGovern, Deval Gor, György Jermendy, Zanfina Ademi, Richard Ofori-Asenso, Marie L. De Bruin, Ken Lee Chin
Publikováno v:
Acta Diabetologica, 58. Springer-Verlag Italia
Aims: Medication adherence and persistence are important determinants of treatment success in type 2 diabetes mellitus (T2DM). This systematic review and meta-analysis evaluated the real-world adherence, persistence, and in-class switching among pati
Autor:
Natalja Genina, Ingrid Hegger, Susanne Kaae, Sofia Kälvemark Sporrong, Netta Beer, Joelle Hoebert, Teresa Leonardo Alves, Marie L. De Bruin
Publikováno v:
Exploratory Research in Clinical and Social Pharmacy, Vol 4, Iss, Pp 100073-(2021)
Exploratory Research in Clinical and Social Pharmacy, 4, 1
Beer, N, Hegger, I, Kaae, S, De Bruin, M L M, Genina, N, Leonardo Alves, T, Hoebert, J & Kälvemark Sporrong, S 2021, ' Scenarios for 3D printing of personalized medicines : A case study ', Exploratory Research in Clinical and Social Pharmacy, vol. 4, 100073 . https://doi.org/10.1016/j.rcsop.2021.100073
Exploratory Research in Clinical and Social Pharmacy, 4, 1
Beer, N, Hegger, I, Kaae, S, De Bruin, M L M, Genina, N, Leonardo Alves, T, Hoebert, J & Kälvemark Sporrong, S 2021, ' Scenarios for 3D printing of personalized medicines : A case study ', Exploratory Research in Clinical and Social Pharmacy, vol. 4, 100073 . https://doi.org/10.1016/j.rcsop.2021.100073
Background3D printing is a promising new technology for medicines' production. It employs additive manufacturing techniques, and is ideal for producing personalized medicines (e.g., patient-tailored dose, dosage form, drug release kinetics).Objective
Autor:
Robert W Platt, Dolores Montero, Morten Andersen, Luz M. León-Muñoz, Helga Gardarsdottir, Sophie Dell'Aniello, Patrick C. Souverein, Sven Schmiedl, Marie L. De Bruin, Olaf H. Klungel, Pierre Ernst, Hendrika A. van den Ham, Consuelo Huerta, Birgit Grave, Mia Aakjær, Elisa Martin Merino, Marietta Rottenkolber
Publikováno v:
Pharmacoepidemiology and Drug Safety, 30(10), 1339. John Wiley and Sons Ltd
Pharmacoepidemiology and Drug Safety
van den Ham, H A, Souverein, P C, Klungel, O H, Platt, R W, Ernst, P, Dell'Aniello, S, Schmiedl, S, Grave, B, Rottenkolber, M, Huerta, C, Martin Merino, E, Leon-Munoz, L M, Montero, D, Andersen, M, Aakjaer, M, De Bruin, M L & Gardarsdottir, H 2021, ' Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies ', Pharmacoepidemiology and Drug Safety, vol. 30, no. 10, pp. 1339-1352 . https://doi.org/10.1002/pds.5317
Pharmacoepidemiology and Drug Safety
van den Ham, H A, Souverein, P C, Klungel, O H, Platt, R W, Ernst, P, Dell'Aniello, S, Schmiedl, S, Grave, B, Rottenkolber, M, Huerta, C, Martin Merino, E, Leon-Munoz, L M, Montero, D, Andersen, M, Aakjaer, M, De Bruin, M L & Gardarsdottir, H 2021, ' Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies ', Pharmacoepidemiology and Drug Safety, vol. 30, no. 10, pp. 1339-1352 . https://doi.org/10.1002/pds.5317
Objective To establish the risk of major bleeding in direct oral anticoagulant (DOAC) users (overall and by class) versus vitamin K antagonist (VKA) users, using health care databases from four European countries and six provinces in Canada. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc229bf3dc8e7a4abb1c104a51f1f82f
https://dspace.library.uu.nl/handle/1874/418897
https://dspace.library.uu.nl/handle/1874/418897
Autor:
Sofia Kälvemark Sporrong, Timo Minssen, Marie L. De Bruin, Marco van de Weert, Anna Birna Almarsdóttir, Hans Hoogland, Louise C. Druedahl
Publikováno v:
BioDrugs, 35(3), 351. Adis International Ltd
Background: A biosimilar is a biological medicine highly similar to another already approved biological medicine (reference product). The availability of biosimilars promotes competition and subsequently lower prices. Changing the current biosimilar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6da294e451f9999aeb37b519b8aa556
https://dspace.library.uu.nl/handle/1874/412271
https://dspace.library.uu.nl/handle/1874/412271